



**Martin Rickenbach**

**Kontakt**

Martin Rickenbach

## Publikationen (35)

Young J, Bucher H, Günthard H, Battegay M, Cavassini M, Schmid P, Staehelin C, Bernasconi E, Calmy A, Rickenbach M, Swiss HIV Cohort Study. Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. *BMC Infect Dis* 2015; 15:382.

Aebi-Popp K, European Collaborative Study in EuroCoord, Thorne C, Hoesli I, Rickenbach M, Scheibner K, Grawe C, Fehr J, Bertisch B, Martinez de Tejada B, Rudin C, Glass T, Mulcahy F, Swiss Mother & Child HIV Cohort Study. Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery. *J Acquir Immune Defic Syndr* 2013; 64:58-65.

Glass T, Marzolini C, Battegay M, Wandeler G, Bernasconi E, Hirschel B, Nicca D, Rickenbach M, Günthard H, Bucher H, Csajka C, Decosterd L, Telenti A, Rotger M, the Swiss HIV Cohort Study. Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy. *PloS one* 2012; 7:e29186.

Audigé A, Taffé P, Rickenbach M, Battegay M, Vernazza P, Nadal D, Speck R. Low Postseroconversion CD4 Count and Rapid Decrease of CD4 Density Identify HIV(+) Fast Progressors. *AIDS Res Hum Retroviruses* 2010; 26:997-1005.

Kouyos R, Bonhoeffer S, Ledergerber B, Rickenbach M, Bernasconi E, Vernazza P, Battegay M, Furrer H, Cavassini M, Hirschel B, Weber R, Klimkait T, Bürgisser P, Shah C, Taffé P, Böni J, Yerly S, von Wyl V, Günthard H. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. *J Infect Dis* 2010; 201:1488-97.

Bucher H, Battegay M, Weber R, Vernazza P, Schiffer V, Fux C, Cavassini M, Bernasconi E, Vallet Y, Glass T, Young J, Rickenbach M, the Swiss HIV Cohort Study. Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. *Antivir Ther* 2010; 15:31-40.

Glass T, Bucher H, Günthard H, Rickenbach M, Bernasconi E, Hirschel B, Vernazza P, Furrer H, De Geest S, Cavassini M, Battegay M, the Swiss HIV Cohort Study. Longitudinal Analysis of Patterns and Predictors of Changes in Self-Reported Adherence to Antiretroviral Therapy: Swiss HIV Cohort Study. *Journal of acquired immune deficiency syndromes (1999)* 2009

Young J, Bucher H, Battegay M, Vernazza P, Tarr P, Hirschel B, Furrer H, Rickenbach M, Bernasconi E, Glass T, Swiss HIV Cohort Study. Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. *Journal of clinical epidemiology* 2009; 62:632-41.

Young J, Battegay M, Bernasconi E, Vernazza P, Cavassini M, Hirschel B, Fux C, Rickenbach M, Günthard H, Bucher H, Swiss HIV Cohort Study. Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. *Antiviral therapy* 2009; 14:771-9.

Ballif M, Weber R, Opravil M, Rickenbach M, Furrer H, Hirschel B, Schmid P, Bernasconi E, Cavassini M, Battegay M, Ledergerber B, Swiss HIV Cohort Study. Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. *PloS one* 2009; 4:e8275.

von Wyl V, Günthard H, Ledergerber B, Rickenbach M, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, Swiss HIV Cohort Study. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2008; 46:1299-309.

Polesel J, Franceschi S, Schmid P, Probst-Hensch N, Levi F, Hasse B, Furrer H, Bouchardy C, Battegay M, Dal Maso L, Rickenbach M, Clifford G, Swiss HIV Cohort Study. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. *AIDS (London, England)* 2008; 22:301-6.

von Wyl V, Günthard H, Ledergerber B, Perrin L, Rickenbach M, Bernasconi E, Vernazza P, Hirschel B, Telenti A, Furrer H, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, for the Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. *Archives of internal medicine* 2007; 167:1782-90.

Ledergerber B, Weber R, Egger M, Schmid P, Bernasconi E, Cavassini M, Hirschel B, Elzi L, Lehmann R, Rickenbach M, Furrer H, Swiss HIV Cohort Study. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2007; 45:111-9.

Glass T, Bucher H, Battegay M, Hirschel B, Cavassini M, Bernasconi E, Furrer H, Rickenbach M, Vernazza P, Weber R, Swiss HIV Cohort Study. Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. *HIV clinical trials* 2007; 8:77-85.

Simcock M, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher H, Battegay M, Koller M, Moirandat-Rytz S, Terziroli B, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson J, Bernasconi E, Swiss HIV Cohort Study. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. *Antiviral therapy* 2007; 12:931-9.

Keiser O, Furrer H, Telenti A, Rickenbach M, Vernazza P, Bernasconi E, Hirschel B, Hirsch H, Opravil M, Fellay J, Swiss HIV Cohort Study. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. *Antiviral therapy* 2007; 12:1157-64.

Elzi L, Furrer H, Rickenbach M, Bernasconi E, Schmid P, Cavassini M, Hirschel B, Weber R, Schlegel M, Swiss HIV Cohort Study. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2007; 44:94-102.

Keiser O, Aebi-Popp K, Bernasconi E, Schmid P, Elzi L, Zinkernagel A, Zellweger C, Chapuis-Taillard C, Wunder D, Martinez de Tejada B, Rickenbach M. Frequency of gynecologic follow-up and cervical cancer screening in the Swiss HIV cohort study. *Journal of acquired immune deficiency syndromes (1999)* 2006; 43:550-5.

Glass T, Battegay M, Hirschel B, Cavassini M, Bernasconi E, Furrer H, Rickenbach M, Vernazza P, Weber R, De Geest S, Bucher H. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. *Journal of acquired immune deficiency syndromes (1999)* 2006; 41:385-92.

Zinkernagel A, Weber R, Schmid P, Bernasconi E, Opravil M, Tarr P, Hirschel B, Battegay M, Furrer H, Rickenbach M, Ledergerber B, von Wyl V, Swiss HIV Cohort Study. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. *Antiviral therapy* 2006; 11:131-42.

Rotger M, Telenti A, Rickenbach M, Bernasconi E, Drechsler H, Vernazza P, Furrer H, Günthard H, Bleiber G, Taffé P, Swiss HIV Cohort Study. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. *The Journal of infectious diseases* 2005; 192:1381-6.

Kaufmann G, Battegay M, Hirschel B, Rickenbach M, Bernasconi E, Cavassini M, Vernazza P, Opravil M, Perrin L, Ledergerber B, Furrer H, Swiss HIV Cohort Study. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2005; 41:361-72.

Rauch A, Furrer H, Evison J, Zinkernagel A, Bernasconi E, Vernazza P, Bucher H, Tarr P, Hirschel B, Weber R, Rickenbach M, Swiss HIV Cohort Study. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2005; 41:395-402.

Tarr P, Telenti A, Ledergerber B, Rickenbach M, Darioli R, Bernasconi E, Vernazza P, Weber R, Battegay M, Hirschel B, Martinez R, Rotger M, Furrer H, Bleiber G, Taffé P, Swiss HIV Cohort Study. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. *The Journal of infectious diseases* 2005; 191:1419-26.

Young J, Battegay M, Vernazza P, Tarr P, Hirschel B, Bernasconi E, Furrer H, Weber R, Rickenbach M, Bucher H. Body fat changes among antiretroviral-naïve patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. *Antiviral therapy* 2005; 10:73-81.

Young J, Battegay M, Vernazza P, Tarr P, Hirschel B, Bernasconi E, Furrer H, Rickenbach M, Weber R, Bucher H. Lipid profiles for antiretroviral-naïve patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. *Antiviral therapy* 2005; 10:585-91.

Glass T, Bucher H, Battegay M, Hirschel B, Cavassini M, Weber R, Rickenbach M, Vernazza P, Young J, Swiss HIV Cohort Study. Is unsafe sexual behaviour increasing among HIV-infected individuals?. *AIDS (London, England)* 2004; 18:1707-14.

Yerly S, Perrin L, Hirschel B, Perneger T, Bernard M, Gebhardt M, Rickenbach M, Bürgisser P, Chanzy B, Furrer H, Battegay M, Vernazza P, Chave J, Kaiser L, Flepp M, Telenti A, Jost S, Swiss HIV Cohort Study. Infrequent transmission of HIV-1 drug-resistant variants. *Antiviral therapy* 2004; 9:375-84.

Kaufmann G, Battegay M, Hirschel B, Rickenbach M, Bernasconi E, Vernazza P, Ledergerber B, Cavassini M, Furrer H, Perrin L, Weber R, Khanna N, Swiss HIV Cohort Study. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection. *Antiviral therapy* 2004; 9:263-74.

Young J, Bucher H, Battegay M, Vernazza P, Telenti A, Hirschel B, Bernasconi E, Furrer H, Rickenbach M, Flepp M, Spirig R, De Geest S, Swiss HIV Cohort Study Group. Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study. *BMJ (Clinical research ed.)* 2004; 328:15.

Kaufmann G, Battegay M, Egger M, Rickenbach M, Bernasconi E, Vernazza P, Ledergerber B, Hirschel B, Telenti A, Furrer H, Opravil M, Pantaleo G, Perrin L, Swiss HIV Cohort Study Group. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. *Archives of internal medicine* 2003; 163:2187-95.

Jaggy C, Hirschel B, Bernasconi E, Vernazza P, Flepp M, Battegay M, Telenti A, Furrer H, Rickenbach M, Egger M, Schwarz C, Ledergerber B, von Overbeck J, Swiss HIV Cohort Study. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. *Lancet* 2003; 362:877-8.

Wolf K, Bucher H, Weber R, Telenti A, Hirschel B, Bernasconi E, Furrer H, Flepp M, Vernazza P, Rickenbach M, Young J, Swiss HIV Cohort Study. Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study. *Journal of acquired immune deficiency syndromes (1999)* 2003; 33:494-9.

Bernasconi E, Telenti A, Rickenbach M, Weber R, Opravil M, Chave J, Boggian K, Hirschel B, Haensel A, Furrer H, Flepp M, Junghans C, Boubaker K, Swiss HIV Cohort Study. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr* 2002; 31:50-5.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)